In a phase I randomised crossover study of 37 healthy adults, 30-min intravenous topiramate (50–200 mg) showed mean relative bioavailability of 97.1% (90% CI 94.6–99.7%) versus oral topiramate, dose-proportional exposure and no serious adverse events.
RCTn = 37
Bamgboye et al. A Phase I study of the pharmacokinetics (PK), bioavailability, dose proportionality, safety, and tolerability of topiramate injection compared to Oral topiramate in healthy adult participants